{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:21Z","timestamp":1761513141224},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00467-012-2186-9","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T11:27:54Z","timestamp":1337945274000},"page":"1953-1959","source":"Crossref","is-referenced-by-count":18,"title":["An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects"],"prefix":"10.1007","volume":"27","author":[{"given":"Desmond","family":"Padhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Langman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Fathallah-Shaykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Warady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Posvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,26]]},"reference":[{"key":"2186_CR1","first-page":"318","volume":"54","author":"GA Block","year":"2000","unstructured":"Block GA (2000) Prevalence and clinical consequences of elevated Ca \u00d7 P product in hemodialysis patients. Clin Nephrol 54:318\u2013324","journal-title":"Clin Nephrol"},{"key":"2186_CR2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","volume":"59","author":"WG Goodman","year":"2001","unstructured":"Goodman WG (2001) Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187\u20131201","journal-title":"Kidney Int"},{"key":"2186_CR3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI114022","volume":"83","author":"JA Delmez","year":"1989","unstructured":"Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E (1989) Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 83:1349\u20131355","journal-title":"J Clin Invest"},{"key":"2186_CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Juppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79:112\u2013119","journal-title":"Kidney Int"},{"key":"2186_CR5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zanie VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"2186_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00467-004-1745-0","volume":"20","author":"TB Drueke","year":"2005","unstructured":"Drueke TB (2005) Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. Pediatr Nephrol 20:399\u2013403","journal-title":"Pediatr Nephrol"},{"key":"2186_CR7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800\u2013807","journal-title":"J Am Soc Nephrol"},{"key":"2186_CR8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","volume":"20","author":"SM Moe","year":"2005","unstructured":"Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani BJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186\u20132193","journal-title":"Nephrol Dial Transplant"},{"key":"2186_CR9","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040\u20134045","journal-title":"Proc Natl Acad Sci USA"},{"key":"2186_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","volume":"366","author":"EM Brown","year":"1993","unstructured":"Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575\u2013580","journal-title":"Nature"},{"key":"2186_CR11","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","volume":"23","author":"GA Block","year":"2008","unstructured":"Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA (2008) Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23:2311\u20132318","journal-title":"Nephrol Dial Transplant"},{"key":"2186_CR12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017\u20131024","journal-title":"J Am Soc Nephrol"},{"key":"2186_CR13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrad DJ, McCary LC, Olson KA, Turner SA, Martin KJ (2005) Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760\u2013771","journal-title":"Kidney Int"},{"key":"2186_CR14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00467-003-1290-2","volume":"18","author":"WG Goodman","year":"2003","unstructured":"Goodman WG (2003) Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 18:1206\u20131210","journal-title":"Pediatr Nephrol"},{"key":"2186_CR15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00467-007-0742-5","volume":"23","author":"DM Silverstein","year":"2008","unstructured":"Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 23:1817\u20131822","journal-title":"Pediatr Nephrol"},{"key":"2186_CR16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","volume":"23","author":"J Muscheites","year":"2008","unstructured":"Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 23:1823\u20131829","journal-title":"Pediatr Nephrol"},{"key":"2186_CR17","doi-asserted-by":"crossref","unstructured":"Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC (2006) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev:CD006254","DOI":"10.1002\/14651858.CD006254"},{"key":"2186_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R (2009) Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 48:303\u2013311","journal-title":"Clin Pharmacokinet"},{"key":"2186_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","volume":"1","author":"GM Chertow","year":"2006","unstructured":"Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J (2006) Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1:305\u2013312","journal-title":"Clin J Am Soc Nephrol"},{"key":"2186_CR20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfn654","volume":"24","author":"M Meola","year":"2009","unstructured":"Meola M, Petrucci I, Barsotti G (2009) Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 24:982\u2013989","journal-title":"Nephrol Dial Transplant"},{"key":"2186_CR21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200544050-00004","volume":"44","author":"D Padhi","year":"2005","unstructured":"Padhi D, Harris RZ, Salfi M, Sullivan JT (2005) No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar\/Mimpara). Clin Pharmacokinet 44:509\u2013516","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00467-012-2186-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T07:36:21Z","timestamp":1642318581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-012-2186-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,26]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s00467-012-2186-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,26]]}}}